🏆 Deal of the Week · CW 7/2022
SpliceBio raised EUR 50 million in a Series A financing round; the valuation was not disclosed. The round was oversubscribed and closed in 2022. Asabys Partners, Gilde Healthcare, New Enterprise Associates, Novartis Venture Fund, UCB Ventures, and Ysios Capital participated in the financing.
SpliceBio — key deal facts
| Company | SpliceBio |
| Founded | 2012 |
| Headquarters | Barcelona, Spain |
| Amount raised | EUR 50M |
| Valuation | Valuation Remains Undisclosed |
| Round | Series A |
| Investors | Asabys Partners (https://asabys.com/) Gilde Healthcare (https://gildehealthcare.com/) New Enterprise Associates (https://www.nea.com/) Novartis Venture Fund (https://www.nvfund.com/) UCB Ventures (https://www.ucbventures.com/) Ysios Capital (https://ysioscapital.com/) |
| Sectors | Biotechnology |
Who invested in SpliceBio?
The syndicate spans three geographies and combines specialist life-science venture capital with strategic corporate venture arms. Novartis Venture Fund and UCB Ventures bring direct pharma sector expertise in ophthalmology and rare disease, while New Enterprise Associates adds transatlantic depth. Asabys Partners, Gilde Healthcare, and Ysios Capital round out the consortium with dedicated European biotech experience.
What does SpliceBio do?
SpliceBio is a clinical-stage biotechnology company headquartered in Barcelona, Spain, founded in 2012. The company develops next-generation gene therapies using its proprietary Protein Splicing platform, which is based on engineered inteins originally developed at Princeton University's Muir Lab. Its technology is designed to treat inherited genetic conditions caused by mutations in large genes that exceed the packaging capacity of conventional viral vectors. Its lead program, SB-007, targets the root cause of Stargardt disease, an inherited retinal dystrophy, with additional pipeline programs in ophthalmology and neurology.
SpliceBio valuation & multiples
Explore the benchmarks: Series A.
Frequently asked questions
How much did SpliceBio raise in its Series A?
SpliceBio raised EUR 50 million in an oversubscribed Series A financing round that closed in 2022.
What is SpliceBio's valuation?
SpliceBio's valuation was not disclosed in connection with its Series A financing.
Who invested in SpliceBio?
The Series A investors were Asabys Partners, Gilde Healthcare, New Enterprise Associates, Novartis Venture Fund, UCB Ventures, and Ysios Capital.
When was SpliceBio founded and where is it based?
SpliceBio was founded in 2012 and is headquartered in Barcelona, Spain.
Source: original announcement — read the full report.